Wilson Sonsini Goodrich & Rosati advised DICE Therapeutics on the deal. DICE Therapeutics, Inc., a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Quanta Therapeutics on the deal. Quanta Therapeutics, Inc., a privately held biopharmaceutical company pioneering complex-directed therapies to treat RAS-driven cancer...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati represented General Atlantic on the transaction. CinCor Pharma, Inc. announced the completion of a $143 million Series B financing. The financing...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised New Enterprise Associates (NEA) and Versant Ventures on the deal. 858 Therapeutics announced the completion of a $60 million Series...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati and Fenwick & West advised DiCE Molecules on the deal. DiCE Molecules, a biopharmaceutical company leveraging its proprietary DNA-encoded library platform...
You must be a Standard 1 Year member to access this content.
